Analyst Consensus ?
ConsensusHold26 ratings
Bullish1350.0%
Neutral1246.2%
Bearish13.8%
1 unmapped firm rating excluded from the percentages.
The Cooper Companies, Inc. · COO · FY2026 Q3 · Calendar Q3 2026
CooperCompanies beats expectations as inventory reduction weighs on vision revenue
The quarter supports a cautiously constructive operating thesis: demand appears resilient in key franchises, but reported vision revenue is temporarily constrained by U.S. inventory reduction and the next phase depends on execution in APAC, product launches, and fertility growth.
Reported After market closeNASDAQHealthcare
$10.78B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.15
Consensus $1.12
EPS surprise
+2.7%
Reported versus consensus
Reported revenue
$1.07B
Consensus $1.10B
Revenue surprise
-2.9%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-14.7%
Event window
SPY move
-0.6%
Same window
Abnormal move
-14.1%
Stock minus SPY
Volume
9.0×
Versus trailing sessions
Subsequent drift
+2.1%
Up to 20 sessions
COOSPY benchmark
Ask FN2 about COO FY2026 Q3
Transcript, numbers and history already loaded
Why did COO fall 14.7% after beating EPS estimates in FY2026 Q3?What changed in COO's guidance and outlook in FY2026 Q3?Give me the bull and bear case for COO after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
CooperCompanies reported an earnings beat and record quarterly free cash flow. CooperVision revenue was flat because of deliberate U.S. inventory reduction, while CooperSurgical grew organically; management completed its strategic review and chose to retain the business.
Guidance delta
Management maintained its outlook while providing modest Q4 guidance; no numerical change is supplied in the transcript analysis.
Key takeaways
- Earnings exceeded consensus and quarterly free cash flow reached a record level.
- CooperVision revenue was flat as the company reduced U.S. channel inventory; management said underlying demand remains healthy.
- MyDay growth, fertility services, genomics adoption, and the decision to retain CooperSurgical shape the outlook.
Management priorities
- Launch MyDay toric multifocal and MyDay MiSight toric lenses.
- Expand global sales, customer marketing, fertility R&D, and genomics offerings.
- Scale the Puerto Rico packaging facility for direct-to-consumer fulfillment.
Follow COO with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$55.29Current
$59Low
$94.75Average
$368High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 20, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Needham | Buy | Buy | Maintain | Sep 15, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Sep 11, 2026 |
| William Blair | Market Perform | Outperform | Downgrade | Sep 10, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Sep 10, 2026 |
| UBS | Neutral | Neutral | Maintain | Sep 10, 2026 |
| Stifel | Buy | Buy | Maintain | Sep 10, 2026 |
| Piper Sandler | Neutral | Overweight | Downgrade | Sep 10, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Sep 10, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Sep 10, 2026 |
| Baird | Neutral | Outperform | Downgrade | Sep 10, 2026 |
| B of A Securities | Neutral | Buy | Downgrade | Sep 10, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Jun 8, 2026 |
| Barclays | Overweight | Overweight | Maintain | Mar 6, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Dec 8, 2025 |
| Goldman Sachs | Sell | Sell | Maintain | Dec 8, 2025 |
| Redburn Atlantic | Neutral | Buy | Downgrade | Oct 4, 2023 |
| Jefferies | Hold | Buy | Downgrade | Oct 11, 2022 |
| Keybanc | Overweight | Downgrade | Aug 28, 2022 | |
| Stephens & Co. | Overweight | Overweight | Maintain | Jun 2, 2022 |
| Guggenheim | Buy | Neutral | Upgrade | Jan 2, 2022 |
| Raymond James | Outperform | Outperform | Maintain | Mar 4, 2021 |
| Oppenheimer | Perform | Perform | Maintain | Sep 3, 2020 |
| BMO Capital | Outperform | Outperform | Maintain | Mar 5, 2019 |
| Cleveland Research | Buy | Neutral | Upgrade | May 15, 2016 |
| PiperJaffray | Overweight | Overweight | Maintain | Dec 4, 2015 |
| Stifel Nicolaus | Buy | Buy | Maintain | Dec 1, 2015 |
| Morgan Keegan | Outperform | Outperform | Maintain | Mar 8, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $55.29. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Anthony Petrone | $75 | $55.22 | +35.6% | Sep 10, 2026 |
| UBS | Analyst unavailable | $66 | $63.48 | +19.4% | Sep 10, 2026 |
| Needham | David Saxon | $73 | $63.48 | +32.0% | Sep 10, 2026 |
| Wells Fargo | Analyst unavailable | $61 | $63.48 | +10.3% | Sep 10, 2026 |
| Stifel Nicolaus | Jonathan Block | $70 | $63.48 | +26.6% | Sep 10, 2026 |
| Robert W. Baird | Jeff Johnson | $61 | $63.48 | +10.3% | Sep 10, 2026 |
| Piper Sandler | Jason Bednar | $59 | $63.48 | +6.7% | Sep 10, 2026 |
| Needham | David Saxon | $86 | $62.02 | +55.5% | Jun 5, 2026 |
| Wells Fargo | Larry Biegelsen | $66 | $62.02 | +19.4% | Jun 5, 2026 |
| Mizuho Securities | Anthony Petrone | $85 | $60.34 | +53.7% | Jun 4, 2026 |
| Piper Sandler | Analyst unavailable | $86 | $61.21 | +55.5% | Jun 1, 2026 |
| Goldman Sachs | Analyst unavailable | $61 | $62.03 | +10.3% | May 27, 2026 |
| Needham | Analyst unavailable | $99 | $80.65 | +79.1% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $98 | $81.29 | +77.2% | Jan 26, 2026 |
| Goldman Sachs | Analyst unavailable | $73 | $83.13 | +32.0% | Jan 9, 2026 |
| Goldman Sachs | Analyst unavailable | $71 | $81.4 | +28.4% | Dec 8, 2025 |
| Barclays | Matt Miksic | $91 | $81.4 | +64.6% | Dec 8, 2025 |
| Robert W. Baird | Analyst unavailable | $98 | $77.03 | +77.2% | Dec 5, 2025 |
| Mizuho Securities | Analyst unavailable | $100 | $77.03 | +80.9% | Dec 5, 2025 |
| Stifel Nicolaus | Jonathan Block | $95 | $77.03 | +71.8% | Dec 5, 2025 |
| Piper Sandler | Analyst unavailable | $94 | $77.03 | +70.0% | Dec 5, 2025 |
| Needham | David Saxon | $100 | $77.03 | +80.9% | Dec 5, 2025 |
| Barclays | Matt Miksic | $85 | $68.37 | +53.7% | Oct 13, 2025 |
| Goldman Sachs | David Roman | $64 | $68.56 | +15.8% | Oct 1, 2025 |
| Robert W. Baird | Jeff Johnson | $85 | $66.18 | +53.7% | Aug 28, 2025 |
| Morgan Stanley | Patrick Wood | $76 | $64.77 | +37.5% | Aug 28, 2025 |
| Stifel Nicolaus | Analyst unavailable | $85 | $64.58 | +53.7% | Aug 28, 2025 |
| Loop Capital Markets | Alan Gould | $100 | $69.55 | +80.9% | Jun 17, 2025 |
| Stifel Nicolaus | Analyst unavailable | $105 | $85 | +89.9% | Mar 7, 2025 |
| Robert W. Baird | Analyst unavailable | $107 | $85 | +93.5% | Mar 7, 2025 |
| Jefferies | Young Li | $115 | $90.14 | +108.0% | Jul 16, 2024 |
| Piper Sandler | Jason Bednar | $115 | $90.23 | +108.0% | May 31, 2024 |
| Robert W. Baird | Jeff Johnson | $118 | $90.23 | +113.4% | May 31, 2024 |
| Mizuho Securities | Anthony Petrone | $110 | $93.34 | +99.0% | Aug 28, 2023 |
| Piper Sandler | Analyst unavailable | $375 | $351.02 | +578.2% | Jan 11, 2023 |
| Citigroup | Analyst unavailable | $368 | $315.67 | +565.6% | Dec 12, 2022 |
| Robert W. Baird | Jeff Johnson | $375 | $311.32 | +578.2% | Aug 24, 2022 |
| Stifel Nicolaus | Jonathan Block | $450 | $316.79 | +713.9% | Jun 14, 2022 |
| Wells Fargo | Larry Biegelsen | $480 | $442.01 | +768.1% | Aug 19, 2021 |
| Jefferies | Raj Denhoy | $112.5 | $98.61 | +103.5% | May 24, 2021 |
Track every rating change on COO the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationThe Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue.…
Historical context
All COO earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AXSM Axsome Therapeutics, Inc. | FY2026 Q2 · Calendar Q3 2026 | -11.0% | +3.8% | Axsome reports strong AUVELITY-led growth as pipeline advances |
| HCA HCA Healthcare, Inc. | FY2026 Q2 · Calendar Q3 2026 | +0.4% | +1.5% | HCA Q2 2026: Payer-Mix Shift Hits EBITDA, Florida Medicaid Boosts, $7B Capex Unveiled |
| MOH Molina Healthcare, Inc. | FY2026 Q2 · Calendar Q3 2026 | +8.6% | -9.7% | Molina Healthcare Raises 2026 EPS Guidance on Duals Strength Despite Marketplace Losses |
| WST West Pharmaceutical Services, Inc. | FY2026 Q2 · Calendar Q3 2026 | +13.9% | -0.8% | West Pharmaceutical Q2 2026: EPS and Revenue Beat, Guidance Raised Again |
| DGX Quest Diagnostics Incorporated | FY2026 Q2 · Calendar Q3 2026 | +10.6% | +8.6% | Quest Diagnostics Beats on Volume and AI Automation, Raises Full-Year Guidance |
| EW Edwards Lifesciences Corporation | FY2026 Q2 · Calendar Q3 2026 | +5.0% | -1.4% | Edwards Lifesciences Beats on Q2, Raises Full-Year Sales Guidance |
Latest beats and misses
Who reports nextBeat on EPS
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
- KRFY2026 Q2 · September 11, 2026+2.8% EPS+2.7% move
- ADBEFY2026 Q3 · September 10, 2026+0.8% EPS+1.4% move
- ORCLFY2027 Q1 · September 10, 2026+10.3% EPS-1.7% move
- SUNBFY2027 Q1 · September 9, 2026+19.2% EPS+5.9% move
Missed on EPS
Get the COO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-09-10T14:19:29.731260+00:00
- FN2 earnings calendar · 2026-09-20T01:23:12.707946+00:00
- Polygon adjusted daily market bars · 2026-09-20T22:40:47.026027+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-20T22:40:47.023238+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.